NCT04740476Phase 2Active not recruiting

An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome

Study sponsor: Stoke Therapeutics, Inc · STOK

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2029-03-31Estimated
Enrollment · participants60Estimated
Source updated2026-02-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety of multiple doses of STK-001. After: Measure: Safety of multiple doses of zorevunersen.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview